Peptide reference
BPC-157
A factual reference on BPC-157 regulatory context and evidence limits. Sources checked 6 September 2026; qualified clinical review pending.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
What this page covers
This page records current public regulatory and evidence boundaries for BPC-157. It does not recommend BPC-157, describe how to use it, or claim that it heals, prevents or treats a condition.
Regulatory context in Australia
The Therapeutic Goods Administration identifies products containing BPC-157 as an example of unapproved peptide products. It states that unapproved peptide products not included in the Australian Register of Therapeutic Goods have not been evaluated by it for safety, quality or effectiveness.
Sources: Therapeutic Goods Administration and Australian Chief Medical Officer
The TGA says it does not have oversight of the ingredients, manufacturing standards, safety or efficacy of unapproved peptide products. It also identifies unknowns including manufacture, sterility for injectable products, effects in the body and the nature and frequency of side effects. This is Australian regulatory context, not a statement about every product in every country.
Sources: Therapeutic Goods Administration and Australian Chief Medical Officer
United States compounding context
The U.S. Food and Drug Administration lists BPC-157 among withdrawn bulk-substance nominations on its compounding-risk page. FDA states that compounded drugs containing BPC-157 may pose immunogenicity and peptide-impurity or active-ingredient-characterisation risks, and that it has identified no or limited safety-related information for proposed routes of administration.
Sources: U.S. Food and Drug Administration
FDA’s July 2026 Pharmacy Compounding Advisory Committee page records discussion of BPC-157 free base and BPC-157 acetate for possible inclusion on the U.S. 503A Bulks List. That process is not evidence of an approved therapeutic use.
Sources: U.S. Food and Drug Administration
Evidence and safety boundary
This pilot does not make efficacy claims because its reviewed public regulator sources do not provide a basis for a treatment recommendation. It does not provide dose, frequency, cycle, injection route, reconstitution, stacking or supply advice.
Do not treat this page as a substitute for a clinician, pharmacist or regulator. If you are considering a health decision, seek advice from an appropriate qualified professional.
Published sources
- Concerns regarding the public health risks associated with unapproved peptide products
Therapeutic Goods Administration and Australian Chief Medical Officer. Published 19 June 2026; accessed 6 September 2026.
Supports: Australian regulatory, safety and product-quality context for unapproved peptide products.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration. Current FDA compounding-risk page; accessed 6 September 2026.
Supports: The stated U.S. compounded-drug risk context only.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
U.S. Food and Drug Administration. Meeting held 23-24 July 2026; accessed 6 September 2026.
Supports: That BPC-157-related substances were considered in the 503A-bulks-list process.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.